AFCR’s Faster Payment System (FPS) ID is 113719686. Donors can now enter this number (instead of AFCR’s full bank account number) to make donations through their online or mobile banking.
CAR-T Cell Therapies are Not Working Against Solid Cancers
Doctors divide cancer into two main types: solid tumor cancers and cancers in the blood. Solid cancer is an abnormal mass of tissue in a ‘solid’ organ such as the breast or prostate.…
THE CHALLENGE ——Patient Circumstances Limit Potential Viable Therapies
Patients afflicted with tumors and cancers are in need of urgent, active intervention in order to have the best possibilities for treatment success and a favorable outcome. The majority of such patients often present…
THE CHALLENGE ——Oral Cancer Survival Rate Has Only Improved 5% in the Last Decade and Patients Can Have a Severely Compromised Quality of Life
Oral cancers, a type of Head and Neck cancer, include the lip, tongue, gums, cheeks, the floor (bottom)…
THE CHALLENGE
——High Incidence and Mortality, Few Viable and Dedicated Drugs
Gastrointestinal (GI) cancers including colorectal, stomach, liver, esophageal, and pancreas have high incidence and mortality. Globally, they have the 2nd, 3rd, 4th, 6th, and 7th largest death tolls, respectively, among all cancers.
In 2020,…
THE CHALLENGE
—Unmet Medical Need for Holistic Cancer Treatment
Cancer is a heterogeneous disease. Heterogeneity in cancer is not limited to differences between different patients, but also occurs within a single patient. This intrapatient or intratumoral heterogeneity can present great challenges for cancer treatment.
This…
Innovation: Therapeutics – anticancer system capable of loco-regional delivery of drug product
Targeted Cancer(s): Solid Tumors, Mucosal Cancers. Initial indication: Oral Cancer
Scientific Leadership/Leadership: Manijeh Goldberg, PhD., President & CEO; James Mackay, PhD., Board Member and Chief Advisor; Nishant Agrawal, MD., Chief Medical Advisor
Stage…
Advanced cancers typically suppress the immune response by multiple mechanisms. By carefully engineering multi-functional antibody therapies, there is the potential for more effective treatment.